Aurinia Pharmaceuticals reported revenue of $83.22M and net income of $37.39M for the quarter ended Jun 2026, up 18.9% year over year. This income statement covers 30 quarters of results from Dec 2016 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Dec2016 | Dec2017 | Dec2018 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | ||||||||||||||||||||||||||||||
| Revenue | 14.67M | 23.40M | 21.62M | 28.19M | 55.78M | 28.43M | 34.41M | 41.49M | 54.52M | 45.09M | 50.30M | 57.19M | 67.77M | 59.87M | 62.47M | 70.01M | 73.47M | 77.11M | 77.70M | 83.22M | ||||||||||
| Cost of RevenueCost of Rev | 0.25M | 0.48M | 0.26M | 1.60M | 2.45M | 1.36M | 0.42M | 1.56M | 6.77M | 5.39M | 7.75M | 8.91M | 6.04M | 5.55M | 8.57M | 7.12M | 8.18M | 8.80M | 6.50M | 6.55M | ||||||||||
| Gross Profit | 14.41M | 22.92M | 21.37M | 26.59M | 53.33M | 27.07M | 33.99M | 39.93M | 47.75M | 39.70M | 42.55M | 48.28M | 61.74M | 54.31M | 53.89M | 62.89M | 65.29M | 68.31M | 71.20M | 76.67M | ||||||||||
| Operating items | ||||||||||||||||||||||||||||||
| Amortization - Intangibles | 0.52M | 0.50M | ||||||||||||||||||||||||||||
| Research & DevelopmentR&D | 20.07M | 11.15M | 12.62M | 11.53M | 10.97M | 9.87M | 13.16M | 12.65M | 13.61M | 10.23M | 5.55M | 4.08M | 3.05M | 8.11M | 5.74M | 7.43M | 8.44M | 10.89M | 7.47M | 13.05M | ||||||||||
| Share-based Compensation (IS)Stock Comp. | 5.44M | 2.84M | ||||||||||||||||||||||||||||
| Selling, General & AdministrativeSG&A | 44.65M | 44.76M | 45.20M | 51.53M | 52.17M | 47.47M | 50.12M | 47.08M | 47.76M | 50.07M | 47.70M | 44.93M | 42.37M | 37.03M | 20.34M | 26.02M | 26.18M | 29.25M | 22.03M | 23.51M | ||||||||||
| Restructuring CostsRestructuring | 6.68M | 1.07M | 15.35M | 1.53M | 0.11M | |||||||||||||||||||||||||
| Other Operating ExpensesOther Opex | -0.06M | 0.28M | -1.43M | 0.48M | 0.31M | 2.17M | -0.29M | 3.63M | -2.65M | -9.07M | 4.12M | 0.29M | -4.57M | 4.51M | -4.43M | -9.25M | -0.93M | 5.07M | -0.28M | 6.23M | ||||||||||
| Operating ExpensesOpex | 65.02M | 56.11M | 59.51M | 64.18M | 65.28M | 56.53M | 63.99M | 57.66M | 70.78M | 74.77M | 63.56M | 58.70M | 56.02M | 61.54M | 40.62M | 49.92M | 43.72M | 43.88M | 36.28M | 36.88M | ||||||||||
| Operating IncomeOp. Inc | -50.35M | -32.70M | -37.88M | -35.99M | -9.50M | -28.10M | -29.58M | -16.17M | -16.26M | -29.67M | -13.25M | -1.51M | 11.75M | -1.67M | 21.85M | 20.08M | 29.75M | 33.24M | 41.42M | 46.34M | ||||||||||
| EBIT | -50.35M | -32.70M | -37.88M | -35.99M | -9.50M | -28.10M | -29.58M | -16.17M | -16.26M | -29.67M | -13.25M | -1.51M | 11.75M | -1.67M | 21.85M | 20.08M | 29.75M | 33.24M | 41.42M | 46.34M | ||||||||||
| Non-operating items | ||||||||||||||||||||||||||||||
| Non Operating Interest Expenses | 0.07M | 1.40M | 1.31M | 1.28M | 1.20M | 1.21M | 1.15M | 1.07M | 1.12M | 1.10M | 1.05M | 1.01M | 0.95M | |||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 4.51M | 4.57M | 4.53M | 4.19M | 4.27M | 3.99M | 3.57M | 3.19M | 3.32M | 3.50M | 3.52M | 3.39M | ||||||||||||||||||
| Net income details | ||||||||||||||||||||||||||||||
| EBT | -50.25M | -32.60M | -37.62M | -35.51M | -8.04M | -25.19M | -25.77M | -12.13M | -13.15M | -26.42M | -10.01M | 1.48M | 14.81M | 1.17M | 24.35M | 22.16M | 31.96M | 35.69M | 43.92M | 48.79M | ||||||||||
| Tax ProvisionsTaxes | 0.01M | 0.73M | 0.01M | 0.01M | 0.95M | 0.85M | 0.44M | -0.64M | 0.30M | 0.45M | 0.74M | 0.80M | 0.50M | -0.30M | 1.00M | 0.64M | 0.41M | -175.15M | 9.60M | 11.40M | ||||||||||
| Profit After TaxPAT | -50.26M | -33.32M | -37.63M | -35.52M | -8.99M | -26.05M | -26.21M | -11.49M | -13.45M | -26.87M | -10.75M | 0.68M | 14.31M | 1.48M | 23.34M | 21.51M | 31.55M | 210.84M | 34.33M | 37.39M | ||||||||||
| Income from Continuing OperationsIncome (Continuing) | -50.26M | -33.32M | -37.63M | -35.52M | -8.99M | -26.05M | -26.21M | -11.49M | -13.45M | -26.87M | -10.75M | 0.68M | 14.31M | 1.48M | 23.34M | 21.51M | 31.55M | 210.84M | 34.33M | 37.39M | ||||||||||
| Consolidated Net IncomeConsol Net Inc. | -50.26M | -33.32M | -37.63M | -35.52M | -8.99M | -26.05M | -26.21M | -11.49M | -13.45M | -26.87M | -10.75M | 0.68M | 14.31M | 1.48M | 23.34M | 21.51M | 31.55M | 210.84M | 34.33M | 37.39M | ||||||||||
| Income towards Parent CompanyParent Net Inc | -50.26M | -33.32M | -37.63M | -35.52M | -8.99M | -26.05M | -26.21M | -11.49M | -13.45M | -26.88M | -10.75M | 0.72M | 14.35M | 1.43M | 23.34M | 21.51M | 31.55M | 210.79M | 34.35M | 37.41M | ||||||||||
| Net Income towards Common StockholdersNet Income | -50.26M | -33.32M | -37.63M | -35.52M | -8.99M | -26.05M | -26.21M | -11.49M | -13.45M | -26.88M | -10.75M | 0.72M | 14.35M | 1.43M | 23.34M | 21.51M | 31.55M | 210.79M | 34.35M | 37.41M | ||||||||||
| Additional items | ||||||||||||||||||||||||||||||
| EPS (Basic) | -0.39 | -0.26 | -0.27 | -0.25 | -0.06 | -0.18 | -0.18 | -0.08 | -0.09 | -0.19 | -0.07 | 0.01 | 0.10 | 0.01 | 0.17 | 0.16 | 0.24 | 1.57 | 0.26 | 0.29 | ||||||||||
| EPS (Diluted) | -0.39 | -0.26 | -0.27 | -0.25 | -0.06 | -0.18 | -0.18 | -0.08 | -0.09 | -0.19 | -0.07 | 0.01 | 0.10 | 0.01 | 0.16 | 0.16 | 0.23 | 1.52 | 0.25 | 0.28 | ||||||||||
| Shares Outstanding | 128.44M | 129.37M | 141.68M | 141.73M | 141.86M | 141.91M | 142.64M | 142.78M | 142.85M | 143.24M | 144.01M | 143.33M | 143.05M | 143.06M | 138.92M | 134.87M | 131.81M | 134.37M | 132.38M | 130.08M | ||||||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 128.44M | 129.37M | 141.68M | 141.73M | 141.86M | 141.91M | 142.64M | 142.78M | 142.85M | 143.24M | 144.01M | 144.11M | 145.65M | 146.19M | 143.20M | 137.53M | 136.01M | 138.70M | 137.64M | 133.53M | ||||||||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 129.60M | 141.60M | 141.74M | 141.89M | 142.11M | 142.27M | 143.03M | 143.37M | 143.60M | 143.83M | 143.69M | 142.98M | 143.11M | 140.88M | 137.75M | 132.67M | 131.84M | 132.32M | 130.77M | 132.91M | ||||||||||
| EBITDA | -49.64M | -33.57M | -37.20M | -35.30M | -8.39M | -29.99M | -28.87M | -15.45M | -11.00M | -35.77M | -8.41M | 3.33M | 16.64M | 3.19M | 26.70M | 24.95M | 34.61M | 38.10M | 46.24M | 51.17M | ||||||||||
| Interest ExpensesInt Expense | 0.07M | 1.40M | 1.31M | 1.28M | 1.20M | 1.21M | 1.15M | 1.07M | 1.12M | 1.10M | 1.05M | 1.01M | 0.95M | |||||||||||||||||
| Tax Rate | 54.13% | 3.38% | 4.13% | 2.90% | 1.29% | 21.86% | 23.37% |
Pull Aurinia Pharmaceuticals's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=AUPH&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "AUPH", "statement": "IS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=AUPH&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();